N-Terminal Acetylation vs C-Terminal Amidation in Peptides

A terminal modification adds only a small chemical group to a peptide, but the experimental consequence can be much larger.

N-terminal acetylation removes the positive charge normally associated with a free N-terminus. C-terminal amidation removes the negative charge of a free carboxylate. Either change can affect proteolysis, secondary structure, membrane interaction, receptor recognition, solubility, and biological activity.

For researchers ordering a synthetic peptide, the important question is not whether terminal capping is generally “better.”

The more useful question is: which terminal state represents the molecule your experiment is intended to test?

What Does Terminal Capping Actually Change?

A conventional synthetic sequence without specified terminal modifications is generally prepared with a free N-terminal amine and a free C-terminal carboxylic acid.

At approximately physiological pH, these termini usually contribute opposite charges. Acetylation or amidation removes those terminal ionizable groups.

The mass differences are straightforward to detect by MS. The biological consequences are less predictable.

For a 40-residue peptide, changing one terminal charge may have a modest effect on total charge. For an 8- or 10-residue peptide, that same change can represent a substantial shift in overall electrostatics.

We think terminal state should therefore be considered part of molecular design, not simply an optional finishing step.

N-Terminal Acetylation: Protection, Charge and Structure

N-terminal acetylation is common in biology and occurs extensively in eukaryotic proteins. Current literature estimates that roughly 50–80% of eukaryotic proteins undergo this modification.

In a synthetic peptide, acetylation converts the terminal amino group into an amide and removes its usual positive charge.

One common reason for requesting Ac– is protection against aminopeptidase-mediated degradation. That rationale is valid in many systems, but it does not mean every acetylated peptide will automatically be more stable.

A Classic Example: MART-1 Peptide Stability

A useful foundational example comes from the melanoma epitope MART-1 (27–35).

The native peptide AAGIGILTV was reported to degrade extremely rapidly in fresh human plasma. Its calculated half-life was only 22 seconds, and CTL-reactive peptide was lost within approximately 3 hours under the experimental conditions.

N-terminal acetylation, C-terminal amidation, and combined terminal capping markedly prolonged peptide stability while retaining immunological recognition.

The native sequence is also available as MART-1 (27–35), Human (AS2705), which provides a useful reference when designing modified analogs for comparative studies.

This example shows why researchers working with short epitopes sometimes investigate capped variants even when the endogenous antigen sequence itself contains free termini.

It also illustrates an important distinction: a stability-engineered analog is not chemically identical to the native epitope.

Acetylation Does Not Always Increase Protease Resistance

Terminal protection is often discussed as if the effect were universal.

Recent experimental evidence shows otherwise.

A 2025 study investigated peptides containing D-amino acids that were already resistant to enzymatic degradation. N-terminal acetylation unexpectedly increased their susceptibility to Proteinase K. For one sequence, the substrate decay-rate constant increased 17.5-fold after acetylation.

The authors linked this result to altered interactions between the modified peptide and the catalytic machinery of serine proteases.

This is an important experimental warning.

Acetylation blocks one potential degradation route, but it can simultaneously change how the rest of the sequence interacts with a protease.

We therefore do not recommend treating Ac– as a guaranteed “stability modification” without considering the sequence and degradation system.

C-Terminal Amidation: A One-Charge Difference That Can Change Activity

C-terminal amidation converts the terminal carboxyl group into a neutral amide.

For many bioactive peptides, this modification is part of the native molecular form rather than an artificial stabilization strategy. Peptidylglycine α-amidating monooxygenase-dependent processing generates the C-terminal amide found in dozens of biologically active peptide systems.

The immediate physicochemical consequence is important:

–COO⁻ → –CONH₂

At approximately neutral pH, amidation therefore makes the peptide effectively about one charge unit more positive than the equivalent free-acid sequence.

For highly cationic peptides, particularly antimicrobial and membrane-active sequences, that difference can materially change behavior.

Amidation Can Affect Membrane Interaction

A 2025 study compared AamAP1-Lys with its C-terminally amidated analog.

Amidation produced faster bactericidal activity, greater membrane permeabilization, improved penetration of Gram-negative bacterial membranes, improved antibiofilm activity, and approximately 2- to 3-fold better selectivity in the experimental systems studied.

The improvement could not be explained solely by “protease protection.” Structural and membrane-interaction changes also contributed.

Figure 1. Effect of C-terminal amidation on AamAP1-Lys antimicrobial performance. The figure should compare the free-carboxyl and amidated forms across representative Gram-negative strains using the published MIC dataset. The data illustrate that the effect of amidation is measurable but organism-dependent. Source: AamAP1-Lys study, 2025.

Recent evidence from other systems supports the same broader conclusion. In a 2025 study of Heliocidin, the synthetic C-terminally amidated peptide showed antibacterial and antifungal activity, while the corresponding free-acid form showed no detectable antimicrobial effect under the reported conditions.

That does not mean C-terminal amidation will improve every antimicrobial peptide.

It means terminal chemistry can become part of the structure–activity relationship.

Real Data: Terminal Chemistry Can Change Peptide Persistence More Than the Terminal Residue

One of the most useful recent studies for synthetic-peptide design came from Rozans and colleagues.

The researchers evaluated peptide libraries with different terminal amino acids and terminal chemistries in the presence of human mesenchymal stromal cells, endothelial cells, and macrophages.

The effect of the C-terminus was substantial.

After 48 hours, peptides with free C-terminal carboxylic acids showed approximately 21% remaining in hMSCs, 19% in hUVECs, and 59% in macrophage systems.

C-terminal amidation increased the corresponding values to approximately 31%, 59%, and 90%.

Adding an amidated C-terminal β-alanine produced approximately 31%, 85%, and 99% remaining, respectively.

Figure 2. C-terminal chemistry affects peptide persistence in cell-containing systems. Free carboxylate, C-terminal amide, and amidated β-alanine variants show markedly different peptide recovery after 48 hours. Data adapted into a new visualization from Rozans SJ et al., 2024.

This dataset is particularly useful because the comparison was not limited to one sequence.

The authors found that terminal chemistry could have a stronger influence on degradation than the identity of the terminal amino acid itself.

For laboratories designing immobilized peptides, cell-adhesion sequences, assay probes, or other peptides exposed to cellular proteases, this is more actionable than simply assuming that a particular terminal residue is “stable.”

Native Peptide or Stability-Engineered Analog?

This distinction should be decided before synthesis.

If the goal is to reproduce a native hormone, toxin, neuropeptide, receptor ligand, or other biologically processed peptide, the published terminal state should normally be reproduced.

A naturally amidated peptide should generally be synthesized as the amidated form when native biological activity is the objective.

Apamin (AS2618) is a good example. Its C-terminal amide is part of the mature 18-residue peptide structure and should not be treated as an arbitrary optional modification.

The situation is different when the peptide represents an internal fragment of a larger protein.

A synthetic epitope cut from the middle of a protein acquires a free N-terminus and C-terminus that did not exist at those positions inside the original protein. Depending on the experiment, researchers may intentionally retain those free termini or cap them to alter stability or better mimic the electrostatic environment of an internal sequence.

There is no single correct choice independent of experimental intent.

Can Terminal Capping Matter More Than 95% versus 98% Purity?

In some experiments, yes.

Purity is easy to place on a purchase order, so it often receives more attention than molecular form.

But a 98% pure peptide carrying the wrong terminal chemistry is still the wrong molecular species if the experiment is intended to reproduce a specific native peptide.

Moving from 95% to 98% HPLC purity does not restore a missing C-terminal amide. It does not replace an unintended free amino group with an acetyl group. It also does not correct an incorrect disulfide connectivity or salt form.

We think this is one of the most important procurement distinctions in custom peptide work: first define the correct molecule, then define how pure that molecule needs to be.

For application-dependent purity selection, see Recommended Peptide Purity.

For information on HPLC, MS, lot documentation, and other analytical options, see Peptide Quality Control.

What Should Be Specified When Ordering a Capped Peptide?

The sequence record should describe the actual molecular form.

The quote, production record, vial label, and Certificate of Analysis should use the same terminal specification.

This becomes particularly important when a project is reordered after several months or transferred to another laboratory member. A terminal modification that exists only in an old email but not in the formal sequence record is an avoidable source of batch-to-batch confusion.

Our Custom Peptide Synthesis service supports N-terminal acetylation, C-terminal amidation, terminal labeling, cyclization, noncanonical amino acids, conjugation, and other project-specific modifications.

Should You Order Both Capped and Uncapped Peptides?

Sometimes that is the most informative experiment.

If a published sequence does not establish which terminal state performs best in your assay, synthesizing a matched pair can provide more useful information than assuming that one form is superior.

For example:

PEPTIDE and Ac-PEPTIDE-NH₂ can be compared under the same buffer, concentration, assay, and analytical conditions.

For more detailed structure–activity work, N-terminal and C-terminal changes can be separated so the effect of each terminus is measured independently.

We think this approach is particularly valuable for short, highly charged peptides. Changing one terminal group can represent a substantial fraction of the molecule's overall electrostatic character.

It is usually better to measure that effect than to assume it.

Terminal Capping Should Follow the Biology

N-terminal acetylation and C-terminal amidation are synthetically straightforward modifications. Their biology is not always straightforward.

Acetylation may reduce aminopeptidase exposure, change local structure, alter charge, or—in some protease systems—unexpectedly increase degradation.

Amidation may reduce C-terminal degradation, increase net positive charge, alter membrane binding, and restore the native molecular form of naturally amidated peptides.

The best terminal design therefore depends on what the experiment is trying to reproduce or improve.

For native peptides, reproduce the native chemistry first.

For stability engineering, identify the degradation mechanism before selecting a modification.

For comparative research, keep terminal chemistry consistent unless it is intentionally being tested as a variable.

For procurement, document the terminal form as carefully as the sequence itself.

Researchers planning modified sequences can explore additional topics in Peptide Modifications & Applications or discuss project-specific designs through Custom Peptide Synthesis.

References

1. Rozans SJ, et al. Quantifying and Controlling the Proteolytic Degradation of Cell Adhesion Peptides. ACS Biomater Sci Eng. 2024.

2. Brinckerhoff LH, et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27–35) peptide: implications for peptide vaccines. Int J Cancer. 1999.

3. Cui S, et al. Research on enhancing enzymatic degradation of anti-digestive peptides containing D-amino acids through N-terminal acetylation. Bioorg Chem. 2025;158:108337.

4. McTiernan N, Kjosås I, Arnesen T. Illuminating the impact of N-terminal acetylation: from protein to physiology. Nat Commun. 2025;16:703.

5. Carboxy-Amidated AamAP1-Lys has Superior Conformational Flexibility and Accelerated Killing of Gram-Negative Bacteria. 2025.

6. Purification and characterization of a novel antimicrobial peptide from visceral tissue of sea urchin, Heliocidaris crassispina. Fish Shellfish Immunol. 2025.

7. Chaudhary A, et al. C-Terminal Amidation: Structural Insights into Enhanced Antimicrobial Peptide Efficacy and Amyloidogenesis. Langmuir. 2025;41:27670–27682.